截至8月20日，博威合金股东户数4.41万，较上期减少5.61%；人均流通股18439股，较上期增加6.19%。 2025年1月-6月，博威合金实现营业收入102.21亿元，同比增长15.21%；归母净利润6.76亿元，同比增长 6.05%。 8月27日，博威合金盘中下跌2.02%，截至09:38，报25.66元/股，成交1.58亿元，换手率0.75%，总市值 208.72亿元。 分红方面，博威合金A股上市后累计派现16.94亿元。近三年，累计派现9.23亿元。 资金流向方面，主力资金净流出1154.01万元，特大单买入110.72万元，占比0.70%，卖出129.43万元， 占比0.82%；大单买入1929.81万元，占比12.18%，卖出3065.11万元，占比19.35%。 博威合金今年以来股价涨29.60%，近5个交易日跌6.35%，近20日涨40.37%，近60日涨48.24%。 今年以来博威合金已经2次登上龙虎榜，最近一次登上龙虎榜为8月13日。 资料显示，宁波博威合金材料股份有限公司位于浙江省宁波市鄞州区云龙镇太平桥，成立日期1994年1 月22日，上市日期2011年1月27日，公司主营业务涉及 ...

8月26日，博威合金盘中下跌2.04%，截至10:13，报26.38元/股，成交4.13亿元，换手率1.90%，总市值 214.58亿元。 资金流向方面，主力资金净流出4798.40万元，特大单买入2810.42万元，占比6.81%，卖出4758.88万 元，占比11.52%；大单买入9698.88万元，占比23.49%，卖出1.25亿元，占比30.39%。 博威合金今年以来股价涨33.24%，近5个交易日涨0.11%，近20日涨41.90%，近60日涨54.81%。 今年以来博威合金已经2次登上龙虎榜，最近一次登上龙虎榜为8月13日。 资料显示，宁波博威合金材料股份有限公司位于浙江省宁波市鄞州区云龙镇太平桥，成立日期1994年1 月22日，上市日期2011年1月27日，公司主营业务涉及高性能、高精度有色合金棒、线、板带新材料的 研发、生产和销售。太阳能电池片及组件的研发、生产和销售;精密切割丝、精密电子线、焊丝的设 计、研发、生产与销售。主营业务收入构成为：新材料产品77.63%，新能源产品21.23%，其他1.14%。 博威合金所属申万行业为：有色金属-金属新材料-其他金属新材料。所属概念板块包括：快充概 ...

Group 1 - Northern Long Dragon is planning to acquire the controlling stake of Henan Zhongsheng and raise matching funds, leading to a stock suspension [1] - The company specializes in the research, design, production, and sales of non-metal composite materials for military vehicle equipment [1] - Koyuan Pharmaceutical's major shareholder plans to reduce their stake by up to 3%, amounting to 324.87 million shares [2] Group 2 - Jiaste Technology's shareholder intends to reduce their stake by up to 3%, totaling 1,428.75 million shares [2] - Chengdi Xiangjiang's subsidiary has won a bid for a data center project with China Mobile, valued at 492 million yuan [3] - Zhongchao Holdings' actual controller sold 223 million shares during a period of stock price fluctuation, representing 0.16% of total shares [4] Group 3 - ST Yushun's stock will resume trading after confirming no significant changes in its operational environment [6] - Xing Shuai Er's shareholder plans to reduce their stake by up to 0.37%, equating to 130 million shares [7] - Weiguang Co. intends to reduce its stake by up to 1.32%, totaling 300 million shares [8] Group 4 - Zhongsheng Pharmaceutical's subsidiary has received ethical approval for two Phase III clinical trials for its innovative peptide drug RAY1225 [9][10] - Nongxin Technology's major shareholder plans to reduce their stake by up to 1.35%, amounting to 135 million shares [12] - Mintai Aluminum has signed a strategic cooperation agreement with Penghui Energy for collaboration in battery technology [14] Group 5 - Youyan Powder's controlling shareholder plans to reduce their stake by up to 1%, totaling 103 million shares [16] - Runjian Co. has been shortlisted for a procurement project with China Mobile, valued at 374 million yuan [17] - Bangyan Technology has terminated its plan to issue shares and raise funds for asset acquisition [18] Group 6 - Xianggang Technology's controlling shareholder intends to reduce their stake by up to 3%, equating to 648.42 million shares [19] - Zhongke Shuguang is undergoing a stock suspension due to a planned share swap merger with Haiguang Information [20]